探索PKG信号作为治疗压力过载,缺血和HFpEF的治疗途径
S Zhazykbayeva1,2, H Budde1,2, M Kaçmaz1,2,3
1Department of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
Expert opinion on therapeutic targets
|September 27, 2024
概括
循环瓜诺辛单酸盐 (cGMP) - 蛋白激酶G (PKG) 途径在心力衰竭 (HF) 中至关重要. 恢复这种信号通路可以改善心脏功能,并为HF患者提供心脏保护作用.
科学领域:
- 心血管医学 心血管医学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种复杂的综合征,涉及心脏重塑和心室功能障碍.
- 病理过程,如压力过载和缺血,有助于HF的发展.
- 循环氨酸单酸 (cGMP) - 蛋白激酶G (PKG) 途径与HF病变发生有关.
研究的目的:
- 审查循环瓜诺辛单酸盐 (cGMP) - 蛋白激酶G (PKG) 途径.
- 讨论cGMP-PKG通路的调制剂.
- 突出针对心力衰竭的cGMP-PKG通路的新型药理学方法.
主要方法:
- 对心血管疾病中cGMP-PKG通路的文献综述.
- 分析心力衰竭的信号机制与保存的喷射分数 (HFpEF).
- 对针对cGMP-PKG途径的药理干预措施的评估.
主要成果:
- 在HF患者和动物模型的心肌细胞中观察到cGMP水平降低和cGMP信号受损.
- 对PKG下游标的低酸化是高频中cGMP信号受损的特征.
- 恢复cGMP-PKG信号显示出改善心肌细胞功能和提供心脏保护的潜力.
结论:
- cGMP-PKG通路在调节心脏收缩性和HF发展方面发挥着至关重要的作用.
- 调节cGMP-PKG信号传递是一种对高频率的有希望的治疗策略.
- 对cGMP-PKG通路的新型药理学增强剂有可能改善心力衰竭的治疗结果.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
146
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
146
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:29Heart Failure II: Pathophysiology
3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3
01:22Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5